15 June 2023
AI influencer tackles TikTok health trend
Alderley Park, Cheshire, UK – 10th June 2023 Contraceptive pill brand, Lovima® has created an AI influencer to help educate young women about hormonal contraception in response to the latest TikTok health trend. #gettingoffbirthcontrol has over nine million views on TikTok, and...
5 June 2023
Cytox brings ground-breaking genetic risk test for Alzheimer's disease to the UK
1st June 2023 - There are currently around 900,000 people in the UK living with dementia, and this number is expected to rise to over 1 million by 2025. Alzheimer's disease (AD) is the most common type of dementia in the UK, accounting for around two-thirds of all cases. Today...
25 May 2023
Oxford BioTherapeutics and Boehringer Ingelheim agree on extension to second multi-year collaboration in cancer immunology
Oxford, UK and San Jose, Calif., 25 May 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announced that it has extended its second multi-year collaboration with...
16 May 2023
Study by Healum demonstrates its platform improves health outcomes for diabetes patients
A randomised control study to explore the impact and efficacy of the Healum Collaborative Care planning Software and App on condition management for Type 2 diabetes (T2D) patients in NHS primary care has produced promising results that have been shown to improve health outcomes.
20 April 2023
Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC
• Trial will investigate OBT076 as monotherapy and in sequence with balstilimab … • CD205, OBT076’s target antigen , is overexpressed in ~ 80 % of ACC tumor biopsy samples … • Recur r ent or metastatic ACC patients currently face poor prognosis and very few treatment ...
6 April 2023
INFEX Therapeutics interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
Alderley Park, Cheshire U.K. Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce that RESP-X, the Company’s new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients, has...
3 April 2023
QV Bioelectronics Awarded £860,000 Innovate UK Boost
31th March 2022, Cheshire, UK - QV Bioelectronics (“QV”), creators of an innovative surgically implanted Electric Field Therapy (EFT) device for the treatment of brain tumours – announces it has been awarded a £860,000 grant under the Combined Investor...
28 March 2023
Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation
Monument Tx CSO to present positive data from first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, at AD/PD conference March 28 th -April 1 st 2023 … Manchester, UK, March 27th, 2023: Monument Therapeutics, a stratified neuroscience company, today...
9 March 2023
Oxford BioTherapeutics to announce new fully integrated ADC Engine at World ADC Conference 2023
• Engine will combine OBT’s internationally recognised target discovery and ADC development capabilities … • OBT will also present a case study and two abstracts focussing on its recent novel target discovery and high-impact partnership outputs leveraging its proprietary...
8 March 2023
Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award
Oxford, UK and San Jose, Calif., 7 March 2023- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody-Drug Conjugate (ADC)-based therapies, announces it has been honoured with two prestigious awards: the ‘Tech...